JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
SALT LAKE CITY - Sera Prognostics Inc. (NASDAQ: SERA), a company dedicated to improving maternal and neonatal health through pregnancy biomarkers, announced the appointment of Jeff Elliott to its Board of Directors effective Thursday. The company also disclosed that Ryan Trimble will retire and step down from the board on June 30, 2025, and Marcus Wilson will not seek re-election at the 2025 Annual Meeting of Stockholders.
Jeff Elliott, who is set to join Sera’s board, brings a wealth of experience from his current role as a senior advisor at Boston Consulting Group and his board membership at Quanterix Corporation (NASDAQ: QTRX). His background includes serving as the chief financial officer and chief operating officer of Exact Sciences (NASDAQ: EXAS) and a senior equity research analyst at Robert W. Baird & Co. Elliott’s career also spans positions at Walgreens and Cap Gemini Ernst & Young.
Elliott’s appointment is part of Sera’s strategy to enhance its board by adding members with substantial expertise in scaling companies within the diagnostics sector. The company’s President and CEO, Zhenya Lindgardt, expressed confidence in Elliott’s ability to contribute to Sera’s market growth, especially following the recent PRIME study results.
Ryan Trimble, who has been with Sera for 14 years, expressed pride in the company’s growth and its position in pregnancy health. He noted that with the PRIME study’s completion and the expected commercialization of the PreTRM® test, the timing was right for his departure. Marcus Wilson echoed a positive outlook on the PRIME study’s success and the potential of the PreTRM® test to impact maternal and neonatal health.
The PreTRM® Test, a key product of Sera Prognostics, is a blood-based biomarker test for the early prediction of spontaneous preterm birth. It is designed to enable physicians to make informed decisions and interventions during pregnancy.
This news comes as Sera Prognostics continues to focus on its mission to reduce healthcare costs by providing early and pivotal pregnancy information. The company’s efforts are particularly significant given the high rate of preterm births in the United States, which has remained over 10% for the past six years according to the 2024 March of Dimes Report Card.
The information in this article is based on a press release statement from Sera Prognostics, Inc.
In other recent news, Exact Sciences reported better-than-expected fourth-quarter earnings, with revenue reaching $713.4 million, surpassing the consensus forecast of $694.92 million. The company’s adjusted earnings per share came in at -$0.06, exceeding analyst estimates of -$0.33. Despite these positive results, Exact Sciences’ stock experienced a decline as investors anticipated more ambitious guidance for 2025. Exact Sciences has set its revenue guidance for 2025 between $3.025 billion and $3.085 billion, aligning with analyst expectations of $3.06 billion.
Additionally, Stifel analysts maintained their Buy rating on Exact Sciences with a $67 price target, acknowledging the company’s fourth-quarter revenue alignment with previous announcements. TD Cowen also reiterated a Buy rating and an $86 price target, citing confidence in Exact Sciences’ conservative guidance and potential sales and EBITDA growth. Meanwhile, BTIG adjusted its price target for Exact Sciences to $65 from $75 but upheld a Buy rating, noting a slight revenue beat for Q4 and strategic investments planned for 2025.
The company has plans to launch three new cancer tests in 2025, including Cologuard Plus, Oncodetect, and Cancerguard. These developments are expected to contribute to the company’s growth trajectory, with analysts from firms like TD Cowen expressing optimism about the impact of new products and operational leverage on Exact Sciences’ future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.